Induction of high level of specific antibody response to the neutralizing epitope ELDKWA on HIV-1 gp41 by peptide-vaccine

被引:19
作者
Liao, MF
Lu, Y
Xiao, Y
Dierich, MP
Chen, YH [1 ]
机构
[1] Tsinghua Univ, Res Ctr Med Sci, Immunol Lab, Beijing 100084, Peoples R China
[2] Tsinghua Univ, Sch Life Sci & Engn, Beijing 100084, Peoples R China
[3] Univ Innsbruck, Ludwig Boltzmann Inst AIDS Res, Inst Hyg, A-6010 Innsbruck, Austria
关键词
epitope-vaccine; neutralizing epitope; HIV-1; gp41;
D O I
10.1016/S0196-9781(00)00179-0
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The monoclonal antibody 2F5 recognizing the neutralizing epitope ELDKWA on the C-domain could neutralize 90% of the investigated HIV-1 isolates. Low levels of ELDKWA-epitope-specific antibodies were observed in HIV-l-infected individuals. To induce high levels of antibodies to ELDKW-epitope, C-domain peptide (P2) was conjugated with a carrier peptide (KGGG)(7)-K (K/G). P2-K/G-conjugate induced high level of antibodies in mice by titer 1:25 600 to ELDKWA-epitope. P2-WG-BSA-conjugate induced antibody response to ELDKWA-epitope (1:320-6400) in mice. The ELDKWA-epitope-specific antibodies of 19.8 and 34.6 mu g/per milliliter serum were isolated from two rabbit antiserums (1:25 600). The levels of ELDKWA-epitope-specific antibodies induced in rabbits were greater than 1 mu g/ml, a level considered to confer long-term protection. These results demonstrate the potential role of the C-domain peptide of gp41 to develop an effective ELDKWA-based epitope/peptide-vaccine against HIV-1. (C) 2000 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:463 / 468
页数:6
相关论文
共 21 条
  • [1] Core structure of gp41 from the HIV envelope glycoprotein
    Chan, DC
    Fass, D
    Berger, JM
    Kim, PS
    [J]. CELL, 1997, 89 (02) : 263 - 273
  • [2] The C domain of HIV-1 gp41 binds the putative cellular receptor protein P62
    Chen, YH
    Xiao, Y
    Wu, WC
    Yang, J
    Sui, SF
    Dierich, MP
    [J]. AIDS, 1999, 13 (09) : 1021 - 1024
  • [3] Identification of a second site in HIV-1 gp41 mediating binding to cells
    Chen, YH
    Dierich, MP
    [J]. IMMUNOLOGY LETTERS, 1996, 52 (2-3) : 153 - 156
  • [4] HIV-1 GP41 CONTAINS 2 SITES FOR INTERACTION WITH SEVERAL PROTEINS ON THE HELPER T-LYMPHOID CELL-LINE, H9
    CHEN, YH
    EBENBICHLER, C
    VORNHAGEN, R
    SCHULZ, TF
    STEINDL, F
    BOCK, G
    KATINGER, H
    DIERICH, MP
    [J]. AIDS, 1992, 6 (06) : 533 - 539
  • [5] Epitope vaccine: a new strategy against HIV-1
    Chen, YH
    Xiao, Y
    Yu, TW
    Dierich, MP
    [J]. IMMUNOLOGY TODAY, 1999, 20 (12): : 588 - 589
  • [6] A strategy for rational design of fully synthetic glycopeptide conjugate vaccines
    Chong, P
    Chan, N
    Kandil, A
    Tripet, B
    James, O
    Yang, YP
    Shi, SP
    Klein, M
    [J]. INFECTION AND IMMUNITY, 1997, 65 (12) : 4918 - 4925
  • [7] Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines
    Connor, RI
    Korber, BTM
    Graham, BS
    Hahn, BH
    Ho, DD
    Walker, BD
    Neumann, AU
    Vermund, SH
    Mestecky, J
    Jackson, S
    Fenamore, E
    Cao, Y
    Gao, F
    Kalams, S
    Kunstman, KJ
    McDonald, D
    McWilliams, N
    Trkola, A
    Moore, JP
    Wolinsky, SM
    [J]. JOURNAL OF VIROLOGY, 1998, 72 (02) : 1552 - 1576
  • [8] Capture of an early fusion-active conformation of HIV-1 gp41
    Furuta, RA
    Wild, CT
    Weng, YK
    Weiss, CD
    [J]. NATURE STRUCTURAL BIOLOGY, 1998, 5 (04) : 276 - 279
  • [9] Association of antibody reactivity to ELDKWA, a glycoprotein 41 neutralization epitope, with disease progression in children perinatally infected with HIV type 1
    Geffin, RB
    Scott, GB
    Melenwick, M
    Hutto, C
    Lai, SH
    Boots, LJ
    McKenna, PM
    Kessler, JA
    Conley, AJ
    [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 1998, 14 (07) : 579 - 590
  • [10] A MACROMOLECULAR MULTICOMPONENT PEPTIDE VACCINE PREPARED USING THE GLUTARALDEHYDE CONJUGATION METHOD WITH STRONG IMMUNOGENICITY FOR HIV-1
    HAMAJIMA, K
    BUKAWA, H
    FUKUSHIMA, J
    KAWAMOTO, S
    KANEKO, T
    SEKIGAWA, KI
    TANAKA, SI
    TSUKUDA, M
    OKUDA, K
    [J]. CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1995, 77 (03): : 374 - 379